Sohm Inc Stock Price, News & Analysis

SOHM, Inc. (SHMN) has appointed Dr. David Aguilar to its Advisory Board as an Expert Medical Advisor. Dr. Aguilar brings extensive expertise in CMC activities for allogeneic cell-based therapies, pharmacology, genome editing, and regenerative medicine. His track record includes co-founding Exeligen Scientific Inc. and establishing regenerative medicine-focused facilities across North America. President and CEO Baron Night expressed confidence that Dr. Aguilar's experience will enhance SOHM's current and future product pipelines. Further appointments are expected soon.

SOHM, Inc. (OTC PINK:SHMN) announced the expansion of its Advisory Board with the appointment of Wm. Dewey Rushing, a former U.S. FDA investigator, as an expert in Validation and Compliance. This move aims to bolster compliance and regulatory expertise, essential for the company's growth strategy. Mr. Rushing brings over 20 years of experience in pharmaceutical quality validation and cGMP compliance, further strengthening SOHM's commitment to portfolio diversification and expanding its foothold in the healthcare sector.

SOHM, Inc. (OTC PINK:SHMN) has announced a collaboration with J Source Industries to manufacture and distribute Brainwise®, an Omega-3 nutraceutical. This partnership is projected to generate $7,500,000 in revenue over three years, with an initial purchase order of $750,000 already secured. The product aims to enhance cognitive health for children and seniors, addressing conditions like Autism and ADHD. The agreement expands SOHM's market presence into Africa, while also targeting North America and the Middle East, in line with its vision of Globalè Prospèro.

SOHM, Inc. (OTC PINK:SHMN) announced a strategic engagement with Sivana Group to enhance its rebranding and global expansion efforts. This collaboration aims to harness Sivana's industry expertise to develop product portfolios and a long-term growth strategy. Mr. Baron Night, CEO of SOHM, emphasized Sivana's capabilities in brand strategy and business relationships. The partnership aligns with SOHM's vision of 'Globalé Prospéro' and seeks to broaden its reach in the pharmaceutical, nutraceutical, and cosmeceutical sectors globally.

SOHM, Inc. (OTC PINK:SHMN) has announced a strategic acquisition of a Southern California pharmaceutical company, enhancing its manufacturing capabilities under FDA licensing. This acquisition allows SOHM to operate a cGMP-compliant contract manufacturing facility, previously operational since 2000, which currently produces 41,000 gallons of semi-solid, liquid, and topical products annually. The facility can expand to over 160,000 gallons per year, paving the way for increased revenues and profitability. The company aims to leverage this opportunity for growth in OTC, cosmeceuticals, and veterinary markets.

SOHM, Inc. (OTC PINK:SHMN) has announced a definitive agreement to acquire a leading pharmaceutical company in Southern California. This acquisition aligns with SOHM's strategy for stability and growth, allowing for the establishment of a manufacturing hub in the USA. The phased acquisition will enable SOHM to manufacture US-branded products in-house, enhancing profitability and opening new contract manufacturing opportunities. The company envisions increased revenues and financial stability following the integration.

SOHM, Inc. (OTC PINK:SHMN) announced a new repeat order for its prescription skincare topical products, aligning with its B2B strategy. These orders, generated from a private label customer, will be distributed nationwide to major pharmacy chains like Wal-Mart and CVS, enhancing revenues for 2021. CEO Baron Night expressed optimism for future updates and growth, aiming to meet financial goals and achieve significant market presence. SOHM, focused on generic pharmaceuticals, aims for continuous growth in emerging markets.

SOHM, Inc. (OTC PINK: SHMN) has completed its due diligence for the acquisition of a Southern California pharmaceutical company. CEO Baron Night announced that the final acquisition agreement is expected to be signed by the end of the current quarter. This acquisition will enable SOHM to manufacture its products in-house in the U.S., enhancing profitability and expanding contract manufacturing opportunities. The move aligns with SOHM's growth strategy and aims to boost revenue and operational stability.

SOHM, Inc. (OTC PINK:SHMN) announced on August 4, 2021, that it has received a mandate for the development and manufacturing of two new human prescription topical products. The first product aims to treat hyperpigmentation, while the second is a combination medication for minor pain and discomfort related to hemorrhoids. SOHM anticipates that these products will be available in major pharmacy chains such as CVS and Wal-Mart by late Q3 or early Q4 2021. CEO Baron Night highlighted that this mandate represents an annualized commitment once the products are on the market.